Spruce Biosciences (SPRB)
NASDAQ:SPRB
Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$70.30
--
Market closed
$70.30
--
Day’s Range― - ―
52-Week Range$4.35 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$135.69M
Enterprise Value$23.39M
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta-10.46
Next Earnings
Aug 17, 2026EPS Estimate
-5.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.60
Shares Outstanding2,752,278
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$158.00Price Target Upside124.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-24.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Solid Equity BaseA very low debt load materially reduces interest expense and refinancing risk, preserving financial optionality for a clinical-stage biotech. With limited leverage, Spruce can prioritize R&D and regulatory milestones without near-term debt service pressure, improving capacity to fund programs from equity or non-dilutive deals.
Recent Capital Raises Bolster RunwayA ~$69M equity financing materially strengthens near-term liquidity to advance late-stage programs and regulatory filings. Coupled with the ATM and loan facility, this reduces immediate refinancing pressure, allowing management to focus on clinical execution and a planned BLA without urgent cash constraints.
Regulatory Clarity And Commercial BuildClearer FDA guidance for an accelerated path and recent hires of experienced regulatory and commercial executives increase the odds of an efficient approval and launch. Combined with rare pediatric incentives, these structural moves strengthen the company's ability to convert clinical data into a viable commercial strategy.
Bears Say
Consistent Cash BurnSustained negative operating and free cash flow indicates the business is not self-financing and remains dependent on external capital. Continued cash burn erodes liquidity over time and forces management to prioritize spending, which could delay programs or require dilutive financings absent milestone-driven inflows or partnerships.
Dependence On External Financing / Dilution RiskRepeated reliance on equity and ATM facilities to fund operations increases shareholder dilution and ties program advancement to access to capital markets. If market conditions tighten or future raises occur at lower prices, the company’s financial flexibility and existing holders’ ownership stakes could be materially impaired.
Pipeline Concentration And Lost Partner IncomeEnding the Kaken deal removes a potential non-dilutive revenue stream and concentrates clinical and commercial risk on TA-ERT and a narrower pipeline. This increases binary outcome risk: failure or delays in the lead program would have outsized adverse effects on the company’s long-term viability and funding prospects.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.35 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $135.69M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 13, 2026. The company reported -$8.94 earnings per share for the quarter, missing the consensus estimate of -$7.934 by -$1.006.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -5.15.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,752,278 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$8.94 in its last earnings report, missing expectations of -$7.934. Following the earnings report the stock price went up 1.562%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$158.00 (124.75% Upside)
$158.00 (124.75% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-155.40%
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$158.00
▲(124.75% Upside)
Technical Analysis
Ownership Overview
66.20% Insiders
1.02% Mutual Funds
12.90% Other Institutional Investors
16.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---